Please Wait.....
Report
Cancer Vaccines Market Report and Forecast 2025-2034
Market Report I 2025-07-29 I 350 Pages I EMR Inc.
The global cancer vaccines market size was valued at USD 8.00 Billion in 2024, driven by the increasing initiatives by pharma giants to develop the most effective cancer vaccine. The market size is anticipated to grow at a CAGR of 11.80% during the forecast period of 2025-2034 to achieve a value of USD 24.41 Billion by 2034.
Global Cancer Vaccines Market Overview
The market is propelled by the researchers putting their maximum efforts into discovering innovative combinations and developing effective cancer vaccines for several types of cancers. The cancer vaccines market demand is driven by the increasing prevalence of cancer cases globally. In 2023, around 20 million new cases of cancer were diagnosed and nearly 10 million deaths were reported across the world. The cancer burden is poised to increase by approximately 60% over the next two decades, further straining health systems, people, and communities. The predicted global burden will increase to about 30 million new cancer cases by 2040, with high incidence in low- and middle-income countries. As a result, industry leaders are coming together to collaborate, perform clinical trials, and develop cancer vaccine candidates.
Rising Adoption of Innovative Alternatives to Offer Precise Treatment
In August 2023, the National Health Service (NHS) England, United Kingdom's publicly funded healthcare system rolled out an anti-cancer jab that can cut down treatment time for some by three-quarters. Atezolizumab (Tencentriq), an immunotherapy drug has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and takes around 7 minutes to administer intravenously, which is significantly lesser than the conventional time span.
The release of this injection is a piece of good news for both the patients and healthcare providers as it facilitates oncologists to provide faster treatment to patients and deliver it conveniently. This approach will likely contribute to increased awareness among patients and offer notable cancer vaccines market growth in the forecast period. The rapid adaptation of innovation by the NHS indicates the commitment to improve the efficiency of health services.
Strategic Collaborations between Market Players
In October 2023, BioNTech SE revealed that Autogene cevumeran (also known as BNT122, RO7198457), a therapeutic individualized cancer vaccine candidate for pancreatic ductal adenocarcinoma (PDAC) treatment was moved to Phase 2 trials after showing promising results in the Phase 1 clinical trials. In the Phase 2 trial, the efficacy is expected to be evaluated in 260 patients, in combination with anti-PD-L1 immune checkpoint inhibitor atezolizumab and chemotherapy. The combination treatment will be tested against the current standard-of-care chemotherapy (mFOLFIRINOX).
The candidate is being jointly developed by BioNTech and Genentech (a member of the Roche Group) and is based on mRNA-based individualized neoantigen-specific immunotherapy (iNeST) platform. The alliance of prominent companies to devise improved and personalized solutions is a major market trend poised to impact the cancer vaccines market share positively in the forecast period.
Global Cancer Vaccines Market Segmentation
Cancer Vaccines Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Technology
- Recombinant Cancer Vaccines
- Whole-Cell Cancer Vaccines
- Viral Vector and DNA Cancer Vaccines
- Other Technologies
Market Breakup by Vaccine Type
- Preventive Vaccine
- Therapeutic Vaccine
Market Breakup by Application
- Prostate Cancer
- Cervical Cancer
- Melanoma
- Bladder Cancer
- Other Applications
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Cancer Vaccines Market Regional Analysis
Geographically, North America is expected to dominate the market during the forecast period. In 2023, the region reported 609,280 cancer related deaths. According to the National Cancer Institute, an estimated 2 million people are expected to be diagnosed with cancer in the United States in 2024. By 2040, the number of people expected to be diagnosed with cancer will increase by 57%, and approximately affect 6.23 million people. As a result, there has been significant emphasis on developing effective solutions for the prevention of cancer associated mortalities.
Europe holds a notable cancer vaccines market share, owing to the presence of prominent academic and research institutions along with an extensive budget to promote research activities. The increasing collaborations between healthcare companies and academic institutions is expected to drive significant market growth in the region. The Asia-Pacific region is witnessing growth, which can be attributed to rising integration of modern technologies into the medical ecosystem. The increasing efforts by the governments of emerging economies to improve the infrastructure is another notable market trend in the region.
Global Cancer Vaccines Market: Competitor Landscape
In February 2023, Moderna, Inc. and Merck announced that the FDA granted a breakthrough therapy designation to mRNA-4157/V940 in combination with pembrolizumab (Keytruda) for the adjuvant treatment of patients with high-risk melanoma following complete resection. The grant was based on the positive results from the phase 2b KEYNOTE-942 trial (NCT03897881). mRNA-4157/V940 is a novel investigational messenger ribonucleic acid (mRNA)-based personalized cancer vaccine made of a single synthetic mRNA coding for up to 34 neoantigens. It works by instigating a natural immune response and generating specific T cell responses.
The key features of the cancer vaccines market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Merck & Co., Inc.
- GlaxoSmithKline plc.
- Dendreon Pharmaceuticals LLC
- Bristol Myers Squibb Company
- AstraZeneca
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Sanofi
- Pfizer Inc.
- Gilead Sciences, Inc.
- Inovio Pharmaceuticals
- Bavarian Nordic
- CureVac SE
- Takeda Pharmaceutical Company Limited
- Cascadian Therapeutics
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Cancer Vaccines Market Overview
3.1 Global Cancer Vaccines Market Historical Value (2018-2024)
3.2 Global Cancer Vaccines Market Forecast Value (2025-2034)
4 Global Cancer Vaccines Market Landscape*
4.1 Global Cancer Vaccines: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Cancer Vaccines: Product Landscape
4.2.1 Analysis by Products
4.2.2 Analysis by Application
5 Global Cancer Vaccines Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter's Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Cancer Vaccines Market Segmentation (218-2034)
6.1 Global Cancer Vaccines Market by Technology
6.1.1 Market Overview
6.1.2 Recombinant Cancer Vaccines
6.1.3 Whole-Cell Cancer Vaccines
6.1.4 Viral Vector and DNA Cancer Vaccines
6.1.5 Other Technologies
6.2 Global Cancer Vaccines Market by Vaccine Type
6.2.1 Market Overview
6.2.2 Preventive Vaccine
6.2.3 Therapeutic Vaccine
6.3 Global Cancer Vaccines Market by Application
6.3.1 Market Overview
6.3.2 Prostate Cancer
6.3.3 Cervical Cancer
6.3.4 Melanoma Bladder Cancer
6.3.5 Other Applications
6.4 Global Cancer Vaccines Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Cancer Vaccines Market (218-2034)
7.1 North America Cancer Vaccines Market (2018-2034) by Technology
7.1.1 Market Overview
7.1.2 Recombinant Cancer Vaccines
7.1.3 Whole-Cell Cancer Vaccines
7.1.4 Viral Vector and DNA Cancer Vaccines
7.1.5 Other Technologies
7.2 North America Cancer Vaccines Market (2018-2034) by Vaccine Type
7.2.1 Market Overview
7.2.2 Preventive Vaccine
7.2.3 Therapeutic Vaccine
7.3 North America Cancer Vaccines Market (2018-2034) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Vaccines Market (218-2034)
8.1 Europe Cancer Vaccines Market (2018-2034) by Technology
8.1.1 Market Overview
8.1.2 Recombinant Cancer Vaccines
8.1.3 Whole-Cell Cancer Vaccines
8.1.4 Viral Vector and DNA Cancer Vaccines
8.1.5 Other Technologies
8.2 Europe Cancer Vaccines Market (2018-2034) by Vaccine Type
8.2.1 Market Overview
8.2.2 Preventive Vaccine
8.2.3 Therapeutic Vaccine
8.3 Europe Cancer Vaccines Market (2018-2034) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Cancer Vaccines Market (218-2034)
9.1 Asia Pacific Cancer Vaccines Market (2018-2034) by Technology
9.1.1 Market Overview
9.1.2 Recombinant Cancer Vaccines
9.1.3 Whole-Cell Cancer Vaccines
9.1.4 Viral Vector and DNA Cancer Vaccines
9.1.5 Other Technologies
9.2 Asia Pacific Cancer Vaccines Market (2018-2034) by Vaccine Type
9.2.1 Market Overview
9.2.2 Preventive Vaccine
9.2.3 Therapeutic Vaccine
9.3 Asia Pacific Cancer Vaccines Market (2018-2034) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 ASEAN
9.3.5 Australia
9.3.6 Others
10 Latin America Cancer Vaccines Market (218-2034)
10.1 Latin America Cancer Vaccines Market (2018-2034) by Technology
10.1.1 Market Overview
10.1.2 Recombinant Cancer Vaccines
10.1.3 Whole-Cell Cancer Vaccines
10.1.4 Viral Vector and DNA Cancer Vaccines
10.1.5 Other Technologies
10.2 Latin America Cancer Vaccines Market (2018-2034) by Vaccine Type
10.2.1 Market Overview
10.2.2 Preventive Vaccine
10.2.3 Therapeutic Vaccine
10.3 Latin America Cancer Vaccines Market (2018-2034) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Cancer Vaccines Market (218-2034)
11.1 Middle East and Africa Cancer Vaccines Market (2018-2034) by Technology
11.1.1 Market Overview
11.1.2 Recombinant Cancer Vaccines
11.1.3 Whole-Cell Cancer Vaccines
11.1.4 Viral Vector and DNA Cancer Vaccines
11.1.5 Other Technologies
11.2 Middle East and Africa Cancer Vaccines Market (2018-2034) by Vaccine Type
11.2.1 Market Overview
11.2.2 Preventive Vaccine
11.2.3 Therapeutic Vaccine
11.3 Middle East and Africa Cancer Vaccines Market (2018-2034) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication Year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Partnership and Collaborations Analysis
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 Merck & Co., Inc.
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 GlaxoSmithKline plc.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Dendreon Pharmaceuticals LLC
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 Bristol Myers Squibb Company
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 AstraZeneca
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 F. Hoffmann-La Roche Ltd.
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Novartis AG
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Sanofi
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Pfizer Inc.
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Gilead Sciences, Inc.
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
18.11 Inovio Pharmaceuticals
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.11.5 Certifications
18.12 Bavarian Nordic
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.12.5 Certifications
18.13 CureVac SE
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.13.5 Certifications
18.14 Takeda Pharmaceutical Company Limited
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisitions
18.14.5 Certifications
18.15 Cascadian Therapeutics
18.15.1 Financial Analysis
18.15.2 Product Portfolio
18.15.3 Demographic Reach and Achievements
18.15.4 Mergers and Acquisitions
18.15.5 Certifications
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security